Stereotactic Body Radiation Therapy for Lung Cancer Treatment: A Systematic Review.
Uloženo v:
| Název: | Stereotactic Body Radiation Therapy for Lung Cancer Treatment: A Systematic Review. |
|---|---|
| Autoři: | Kazemi, Rahele, Tahmasbi, Marziyeh |
| Zdroj: | Reports of Radiotherapy & Oncology; 2025 Supplement, Vol. 11, p22-23, 2p |
| Témata: | LUNG cancer, STEREOTACTIC radiotherapy, METASTASIS, SAFETY, PATIENT selection, TREATMENT effectiveness |
| Abstrakt: | Background: Stereotactic body radiation therapy (SBRT) has emerged as a precise and effective treatment modality for lung, prostate, liver, and pancreatic cancers, as well as spine, neck, and lymph nodes, leveraging advanced imaging techniques and highly focused radiation beams to deliver ablative doses. This systematic review evaluates the clinical efficacy, advantages, and limitations of SBRT in treating early-stage lung cancer and lung oligometastases. The ability of SBRT to minimize damage to healthy tissues while achieving high local control rates makes it a valuable option for patients unsuitable for surgery or those with inoperable tumors. A comprehensive literature review of recent studies on SBRT, focusing on treatment outcomes, toxicity profiles, and patient selection criteria was carried out. Key parameters analyzed included radiation dosage, treatment duration, and the role of concurrent therapies. Special attention was given to SBRT applicability in central and ultra-central lung tumors, where toxicity risks remain challenging. Methods: PubMed, Science Direct, Web of Science, and Google Scholar databases were explored up to October 2024, using different combinations of the keywords: "Stereotactic Body Radiation Therapy", "SBRT", "Treatment Outcome", "Early-Stage", "Oligometastatic", and "Lung Cancer". Finally, 10 of the most recent and relevant records were included in the study. Results: The reviewed records demonstrated that SBRT offers high local tumor control and low toxicity rates in early-stage and oligometastatic lung cancers. However, potential adverse effects, including pneumonitis and esophagitis, necessitate careful patient selection and individualized treatment planning. The reviewed records highlighted the adaptability of SBRT in treating tumors near critical structures through advanced techniques like proton beam therapy. Conclusions: Based on the results of the reviewed records, it can be concluded that SBRT is a viable alternative to surgery for lung cancer patients, providing effective tumor control with reduced treatment durations. Nevertheless, the application of SBRT for supracentral tumors demands caution due to higher toxicity risks. Future research should explore optimizing SBRT protocols and integrating immunotherapy to enhance outcomes. [ABSTRACT FROM AUTHOR] |
| Copyright of Reports of Radiotherapy & Oncology is the property of Brieflands and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Databáze: | Complementary Index |
Nájsť tento článok vo Web of Science | Abstrakt: | Background: Stereotactic body radiation therapy (SBRT) has emerged as a precise and effective treatment modality for lung, prostate, liver, and pancreatic cancers, as well as spine, neck, and lymph nodes, leveraging advanced imaging techniques and highly focused radiation beams to deliver ablative doses. This systematic review evaluates the clinical efficacy, advantages, and limitations of SBRT in treating early-stage lung cancer and lung oligometastases. The ability of SBRT to minimize damage to healthy tissues while achieving high local control rates makes it a valuable option for patients unsuitable for surgery or those with inoperable tumors. A comprehensive literature review of recent studies on SBRT, focusing on treatment outcomes, toxicity profiles, and patient selection criteria was carried out. Key parameters analyzed included radiation dosage, treatment duration, and the role of concurrent therapies. Special attention was given to SBRT applicability in central and ultra-central lung tumors, where toxicity risks remain challenging. Methods: PubMed, Science Direct, Web of Science, and Google Scholar databases were explored up to October 2024, using different combinations of the keywords: "Stereotactic Body Radiation Therapy", "SBRT", "Treatment Outcome", "Early-Stage", "Oligometastatic", and "Lung Cancer". Finally, 10 of the most recent and relevant records were included in the study. Results: The reviewed records demonstrated that SBRT offers high local tumor control and low toxicity rates in early-stage and oligometastatic lung cancers. However, potential adverse effects, including pneumonitis and esophagitis, necessitate careful patient selection and individualized treatment planning. The reviewed records highlighted the adaptability of SBRT in treating tumors near critical structures through advanced techniques like proton beam therapy. Conclusions: Based on the results of the reviewed records, it can be concluded that SBRT is a viable alternative to surgery for lung cancer patients, providing effective tumor control with reduced treatment durations. Nevertheless, the application of SBRT for supracentral tumors demands caution due to higher toxicity risks. Future research should explore optimizing SBRT protocols and integrating immunotherapy to enhance outcomes. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 23453192 |